AZD0292
Phase 2Recruiting 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Bronchiectasis With Pseudomonas Aeruginosa Colonization
Conditions
Bronchiectasis With Pseudomonas Aeruginosa Colonization
Trial Timeline
Nov 6, 2025 → Jun 14, 2028
NCT ID
NCT07088926About AZD0292
AZD0292 is a phase 2 stage product being developed by AstraZeneca for Bronchiectasis With Pseudomonas Aeruginosa Colonization. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07088926. Target conditions include Bronchiectasis With Pseudomonas Aeruginosa Colonization.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07088926 | Phase 2 | Recruiting |
Competing Products
20 competing products in Bronchiectasis With Pseudomonas Aeruginosa Colonization
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Benralizumab + Placebo to Benralizumab | AstraZeneca | Phase 3 | 77 |
| AZD9668 + Placebo | AstraZeneca | Phase 2 | 52 |
| AZD5069 + Placebo | AstraZeneca | Phase 2 | 52 |
| TIP + TIP and placebo + Placebo | Novartis | Phase 2 | 52 |
| Ciprofloxacin DPI (BAYQ3939) + Placebo | Novartis | Phase 3 | 77 |
| Placebo to Ciprofloxacin DPI (BAYQ3939) | Novartis | Pre-clinical | 23 |
| Ciprofloxacin (BAYQ3939) dry powder for inhalation + Ciprofloxacin (BAYQ3939) dry powder for inhalation + Placebo + Placebo | Novartis | Phase 3 | 77 |
| QBW251 + Placebo | Novartis | Phase 2 | 52 |
| Ciprofloxacin (Cipro, BAYQ3939) + Placebo | Novartis | Phase 2 | 52 |
| AZLI + Placebo | Gilead Sciences | Phase 3 | 76 |
| Aztreonam lysine | Gilead Sciences | Approved | 84 |
| AZLI | Gilead Sciences | Phase 2 | 51 |
| AZLI + Placebo | Gilead Sciences | Phase 3 | 76 |
| Itepekimab (SAR440340) + Placebo | Sanofi | Phase 2 | 51 |
| CSL787 + Placebo | CSL | Phase 1 | 32 |
| CSL787 + Placebo | CSL | Phase 2 | 51 |
| HSK31858, tablet + Placebo | Haisco Pharmaceutical Group | Phase 3 | 74 |
| HSK31858 + placebo | Haisco Pharmaceutical Group | Phase 2 | 49 |
| Group A + Group B | Bayer | Pre-clinical | 20 |
| BAY85-8501 + Placebo | Bayer | Phase 2 | 49 |